GHRP-6: Growth Hormone Releasing Peptide Guide

GHRP-6 (Growth Hormone Releasing Peptide-6) is a synthetic hexapeptide that was among the first GH secretagogues developed — synthesized in the 1980s as a research tool to study growth hormone regulation. It binds the ghrelin receptor (GHSR-1a) and stimulates a potent pulse of GH release from the pituitary. While newer secretagogues like ipamorelin have largely superseded it for clinical applications due to their cleaner side effect profile, GHRP-6 remains relevant for its unique combination of strong GH release and potent appetite stimulation — which makes it specifically useful in certain contexts.

Mechanism of Action

GHRP-6 is a synthetic ghrelin mimetic. It binds the GHSR-1a receptor on pituitary somatotrophs to trigger GH release, and also activates ghrelin receptors in the hypothalamus to stimulate appetite and inhibit somatostatin tone.

Where GHRP-6 differs from selective secretagogues like ipamorelin is in its receptor binding breadth. GHRP-6 also activates:

• Adrenal GHSR-1a receptors: causes modest cortisol and ACTH release
• Hypothalamic ghrelin receptors: produces strong hunger stimulation
• Pituitary lactotrophs: causes modest prolactin release

These additional receptor activations are the source of GHRP-6's side effects — and also its utility for appetite stimulation in specific populations.

GH Release Potency

GHRP-6 produces a dose-dependent GH pulse. In human studies:

• 1 mcg/kg intravenously produces a peak GH response of approximately 20–30 ng/mL
• GHRP-6 is more potent per mcg than GHRP-2 in some studies, though GHRP-2 is generally considered the more potent secretagogue overall
• The GH response is significantly enhanced when GHRP-6 is combined with a GHRH analog (sermorelin or CJC-1295) — the two classes of secretagogues are synergistic regardless of which GHRP is used

Appetite Stimulation: Liability or Feature

GHRP-6's potent hunger-stimulating effects are well-documented. Users consistently report intense hunger within 30–60 minutes of injection — particularly for carbohydrate-rich foods. This is a direct ghrelin receptor effect in the hypothalamus.

This is a disadvantage for: Individuals using GH secretagogues for fat loss or body composition improvement, who do not want increased caloric intake.

This is an advantage for: Athletes in bulking phases who need to force higher caloric intake, individuals with poor appetite (post-illness, elderly), or cancer patients experiencing cachexia.

Some practitioners use GHRP-6 specifically as an appetite stimulant for patients struggling to maintain caloric intake, with GH elevation as a secondary benefit.

Dosage Protocol

Standard dosing:

• 100–300 mcg subcutaneously per injection
• 1–3 times daily

Timing:

• Most effective on an empty stomach (as with all GH secretagogues)
• Pre-sleep dose most important for GH optimization
• Pre-workout dose to enhance fat utilization during exercise

Combination with GHRH analog:

• GHRP-6 100–200 mcg + sermorelin 200 mcg, or
• GHRP-6 100–200 mcg + Mod GRF 1-29 100 mcg
• Inject simultaneously for synergistic GH pulse

Saturation dose: GH receptor response saturates at approximately 100–150 mcg. Doses beyond 150 mcg per injection do not proportionally increase GH release; they primarily increase side effects, particularly appetite stimulation.

Research Evidence

GHRP-6 has an extensive research history dating to the 1980s. Key findings include:

GH deficiency: Studies by Bowers and colleagues in the 1980s and 90s established GHRP-6 as an effective GH stimulus in both normal and GH-deficient subjects.

Cardiac protection: Animal studies show GHRP-6 has direct cardioprotective effects through non-GH mechanisms — it activates anti-apoptotic pathways in cardiomyocytes and reduces infarct size after cardiac ischemia. A clinical trial in Cuba explored GHRP-6 for burn wound healing and diabetic foot ulcers, with positive results.

Burn wound healing: Cuban researchers published clinical data on GHRP-6 gel applied topically to chronic wounds, showing accelerated healing — an application that has no direct GH-mediated mechanism and suggests tissue-level ghrelin receptor activity.

Side Effects

• Intense hunger (most common): Predictable, dose-dependent, occurs 30–60 minutes post-injection
• Water retention: Related to GH elevation
• Cortisol elevation: Modest; typically does not cause clinically significant hypercortisolism at standard doses
• Prolactin elevation: Modest; may cause symptoms (fatigue, libido changes) at high doses or in sensitive individuals
• Numbness/tingling: GH-related fluid shifts
• Fatigue: Some users report post-injection fatigue, possibly cortisol-related

FAQ

Is GHRP-6 better than ipamorelin? For most applications, ipamorelin is preferred because it produces similar GH release without cortisol, prolactin, or appetite stimulation. GHRP-6 is specifically preferred when appetite stimulation is a desired outcome.

Can GHRP-6 cause acromegaly? Acromegaly (pathological GH excess) results from chronic supraphysiological GH levels — typically from pituitary tumors. GHRP-6 at standard doses produces physiological GH pulses that are self-limiting due to natural somatostatin feedback. Risk of acromegaly from GHRP-6 at research doses is theoretical rather than documented.

Should I take GHRP-6 before or after training? A pre-workout dose (30 minutes before training) can enhance GH release during exercise. However, the resulting hunger may be uncomfortable during training. Many users prefer a post-workout dose when they intend to eat shortly after, using the hunger stimulation to support a large post-workout meal.

Related Articles

• Ghrelin Mimetics: How GHRP Peptides Stimulate Growth Hormone
• Afamelanotide: FDA-Approved Melanocyte Peptide
• AOD-9604: HGH Fragment for Fat Loss
• Argireline: The Topical Peptide Alternative to Botox?
• Bacteriostatic Water for Peptides: Why It Matters and How to Use It

Track your supplements in Optimize.